GlassScriptPhysician profile
Morgan M Hemer
NPI 1558986257
$6,151.59
in general payments reported to CMS, 2019-2025
24 companies · $1,824 in 2025
The $1,824 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $1,378 · 2023: $1,198 · 2024: $1,529 · 2025: $1,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507 · Education: $44.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.24 |
| Education | $44.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,601.07 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $812.74 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $686.52 | 2022-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $671.35 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $535.37 | 2023-2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $291.00 | 2022-2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $261.27 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $222.63 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $157.63 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Celgene Corporation | $156.65 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $112.32 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $92.83 | 2023-2025 | Linzess |
| Amgen INC. | $83.27 | 2022 | |
| Intercept Pharmaceuticals, INC. | $68.86 | 2022-2024 | Ocaliva |
| Organon LLC | $59.49 | 2023-2024 | Renflexis, Hadlima |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $55.83 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $49.14 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $45.23 | 2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.90 | 2023 | Cyltezo |
| Genzyme Corporation | $44.34 | 2023-2025 | |
| Gilead Sciences, INC. | $43.92 | 2024-2025 | |
| Madrigal Pharmaceuticals | $24.28 | 2025 | Rezdiffra |
| Ucb, INC. | $18.47 | 2024 | Cimzia |
| Nestle Healthcare Nutrition INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.